Phase III results for the Combo Dual Therapy Stent for CAD - Orbus Neich
Orbus Neich has announced long-term results from its REMEDEE Trial of the COMBO Dual Therapy Stent for patients with Coronary Artery Disease. In addition to showing that the stent shows no late target lesion revascularization, the results demonstrate that the stent proactively promotes functional vessel healing.
Key findings include the facts that target lesion revascularization remained stable at 5.7 percent in both years two and three of the follow up on the REMEDEE trial. In addition, there were no thrombotic events over three years. Complete polymer degradation and drug release by 90 days were also observed. Results were released during EuroPCR 2014.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins